Compartilhar
Informação da revista

Estatísticas

Siga este link para acessar o texto completo do artigo

LONG-TERM FOLLOW-UP FROM THE PHASE 1/2 MAJESTEC-1 TRIAL OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS BY LINES OF THERAPIES
LJ Costaa, NWCJV Donkb, L Rosinolc, R Popatd, Be semere, J Martinez-Lopezf, D Trancuccig, T Stephensonh, K Chastaing, N Bahlisi
a University of Alabama at Birmingham, Birmingham, United States
b Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
c Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain
d University College London Hospitals, NHS Foundation Trust, London, United Kingdom
e University of Tübingen, Tübingen, Germany
f Hematological Malignancies Clinical Research Unit, Hospital 12 de Octubre Universidad Complutense, Centro Nacional de Investigaciones Oncológicas CIBERONC, Madrid, Spain
g Johnson & Johnson Innovative Medicine, Raritan, United States
h Johnson & Johnson Innovative Medicine, Spring House, United States
i Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada
Ver más
Lido
1056
Vezes
que se leu este artigo
229
Total PDF
827
Total HTML
Compartilhar estatísticas
Informação do artigo
ISSN: 25311379
Idioma original: Inglês
Dados atualizados diariamente
Ano/Mês Html Pdf Total
2025 7 7 1 8
2025 6 92 22 114
2025 5 128 19 147
2025 4 96 16 112
2025 3 95 18 113
2025 2 92 29 121
2025 1 163 34 197
2024 12 40 18 58
2024 11 80 44 124
2024 10 34 28 62

Siga este link para acessar o texto completo do artigo

Idiomas
Hematology, Transfusion and Cell Therapy